FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2797658822> ?p ?o ?g. }

• W2797658822 endingPage "20218" @default.
• W2797658822 startingPage "20213" @default.
• W2797658822 abstract "// Tamio Okimoto 1 , Yukari Tsubata 1 , Takamasa Hotta 1 , Megumi Hamaguchi 1 , Takae Okuno 1 , Yohei Shiratsuki 1 , Akari Kodama 1 , Mika Nakao 1 , Yoshihiro Amano 1 , Shunichi Hamaguchi 1 , Noriaki Kurimoto 1 , Reiko Tobita 2 and Takeshi Isobe 1 1 Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, Shimane, Japan 2 Department of Dermatology, Shimane University Faculty of Medicine, Shimane, Japan Correspondence to: Tamio Okimoto, email: okimoto@med.shimane-u.ac.jp Keywords: alectinib; anaplastic lymphoma kinase; ceritinib; leukocytoclastic vasculitis; non-small cell lung cancer Received: January 06, 2018      Accepted: February 27, 2018      Published: April 13, 2018 ABSTRACT Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) dramatically improve progression-free survival compared to cytotoxic agents. It is therefore important to manage patients with ALK-TKIs until drug resistance occurs. Leukocytoclastic vasculitis (LCV) is a rare complication during cancer treatment and is associated with a variety of factors. Currently, it is unclear whether we should withdraw a treatment when drug-induced LCV develops. We report a 40-year-old man with advanced pulmonary adenocarcinoma harboring the EML4-ALK fusion protein who developed LCV during ceritinib treatment. Four weeks after withdrawing ceritinib, we could successfully perform rechallenge with ceritinib at the normal dose. Rapid and massive tumor apoptosis due to ceritinib treatment may lead to neoantigen release and immune complexes deposition. To the best of our knowledge, we report the first case of LCV in a patient during ALK-TKI treatment. Following this occurrence, we were able to successfully perform rechallenge with ceritinib. Therefore, key drugs used in a patient’s treatment regimen should not be discontinued without careful evaluation, and we should also consider the possibility of rechallenge." @default.
• W2797658822 created "2018-04-24" @default.
• W2797658822 creator A5002493998 @default.
• W2797658822 creator A5008727240 @default.
• W2797658822 creator A5012343948 @default.
• W2797658822 creator A5039516486 @default.
• W2797658822 creator A5051103266 @default.
• W2797658822 creator A5051257160 @default.
• W2797658822 creator A5052143141 @default.
• W2797658822 creator A5053370908 @default.
• W2797658822 creator A5054929376 @default.
• W2797658822 creator A5061191942 @default.
• W2797658822 creator A5062944401 @default.
• W2797658822 creator A5064121043 @default.
• W2797658822 creator A5074547821 @default.
• W2797658822 date "2018-04-13" @default.
• W2797658822 modified "2023-09-26" @default.
• W2797658822 title "Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein" @default.
• W2797658822 cites W1522852801 @default.
• W2797658822 cites W1976887517 @default.
• W2797658822 cites W2003520876 @default.
• W2797658822 cites W2009275821 @default.
• W2797658822 cites W2010271425 @default.
• W2797658822 cites W2012104399 @default.
• W2797658822 cites W2014611691 @default.
• W2797658822 cites W2050249255 @default.
• W2797658822 cites W2053062982 @default.
• W2797658822 cites W2055402151 @default.
• W2797658822 cites W2063287018 @default.
• W2797658822 cites W2078229309 @default.
• W2797658822 cites W2094420365 @default.
• W2797658822 cites W2099530756 @default.
• W2797658822 cites W2107679713 @default.
• W2797658822 cites W2116444413 @default.
• W2797658822 cites W2116474403 @default.
• W2797658822 cites W2134118673 @default.
• W2797658822 cites W2166768903 @default.
• W2797658822 cites W2170663019 @default.
• W2797658822 cites W2296203814 @default.
• W2797658822 cites W2342239822 @default.
• W2797658822 cites W2398575120 @default.
• W2797658822 cites W2437729260 @default.
• W2797658822 cites W2613260339 @default.
• W2797658822 cites W2624310346 @default.
• W2797658822 cites W2780354891 @default.
• W2797658822 cites W3023813254 @default.
• W2797658822 cites W99599613 @default.
• W2797658822 doi "https://doi.org/10.18632/oncotarget.24765" @default.
• W2797658822 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5929456" @default.
• W2797658822 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29732013" @default.
• W2797658822 hasPublicationYear "2018" @default.
• W2797658822 type Work @default.
• W2797658822 sameAs 2797658822 @default.
• W2797658822 citedByCount "4" @default.
• W2797658822 countsByYear W27976588222018 @default.
• W2797658822 countsByYear W27976588222020 @default.
• W2797658822 countsByYear W27976588222021 @default.
• W2797658822 countsByYear W27976588222023 @default.
• W2797658822 crossrefType "journal-article" @default.
• W2797658822 hasAuthorship W2797658822A5002493998 @default.
• W2797658822 hasAuthorship W2797658822A5008727240 @default.
• W2797658822 hasAuthorship W2797658822A5012343948 @default.
• W2797658822 hasAuthorship W2797658822A5039516486 @default.
• W2797658822 hasAuthorship W2797658822A5051103266 @default.
• W2797658822 hasAuthorship W2797658822A5051257160 @default.
• W2797658822 hasAuthorship W2797658822A5052143141 @default.
• W2797658822 hasAuthorship W2797658822A5053370908 @default.
• W2797658822 hasAuthorship W2797658822A5054929376 @default.
• W2797658822 hasAuthorship W2797658822A5061191942 @default.
• W2797658822 hasAuthorship W2797658822A5062944401 @default.
• W2797658822 hasAuthorship W2797658822A5064121043 @default.
• W2797658822 hasAuthorship W2797658822A5074547821 @default.
• W2797658822 hasBestOaLocation W27976588221 @default.
• W2797658822 hasConcept C117643217 @default.
• W2797658822 hasConcept C126322002 @default.
• W2797658822 hasConcept C143998085 @default.
• W2797658822 hasConcept C2776232967 @default.
• W2797658822 hasConcept C2776256026 @default.
• W2797658822 hasConcept C2779220645 @default.
• W2797658822 hasConcept C2779750558 @default.
• W2797658822 hasConcept C502942594 @default.
• W2797658822 hasConcept C71924100 @default.
• W2797658822 hasConceptScore W2797658822C117643217 @default.
• W2797658822 hasConceptScore W2797658822C126322002 @default.
• W2797658822 hasConceptScore W2797658822C143998085 @default.
• W2797658822 hasConceptScore W2797658822C2776232967 @default.
• W2797658822 hasConceptScore W2797658822C2776256026 @default.
• W2797658822 hasConceptScore W2797658822C2779220645 @default.
• W2797658822 hasConceptScore W2797658822C2779750558 @default.
• W2797658822 hasConceptScore W2797658822C502942594 @default.
• W2797658822 hasConceptScore W2797658822C71924100 @default.
• W2797658822 hasIssue "28" @default.
• W2797658822 hasLocation W27976588221 @default.
• W2797658822 hasLocation W27976588222 @default.
• W2797658822 hasLocation W27976588223 @default.
• W2797658822 hasLocation W27976588224 @default.
• W2797658822 hasOpenAccess W2797658822 @default.
• W2797658822 hasPrimaryLocation W27976588221 @default.

• next